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of reduced systemic vascular resistance (SVR).1 This
systemic inflammatory response syndrome may con-
tribute significantly to postoperative morbidity and
T he use of cardiopulmonary bypass may result in asevere systemic inflammatory syndrome character-
ized by a hyperdynamic circulatory state in the presence
Background: The transcription factor nuclear factor k B mediates the
expression of a number of inflammatory genes involved in the whole-
body inflammatory response to injury. We and others have found that
dithiocarbamates specifically inhibit nuclear factor k B–mediated tran-
scriptional activation in vitro. Objective: We hypothesized that inhibition
of nuclear factor k B with dithiocarbamate treatment in vivo would
attenuate interleukin 1a –mediated hypotension in a rabbit model of sys-
temic inflammation. Methods: New Zealand White rabbits were anes-
thetized and cannulated for continuous hemodynamic monitoring dur-
ing 240 minutes. Rabbits were treated intravenously with either
phosphate-buffered saline solution or 15 mg/kg of a dithiocarbamate,
either pyrrolidine dithiocarbamate or proline dithiocarbamate, 60 min-
utes before the intravenous infusion of 5 m g/kg interleukin 1a . Nuclear
factor k B activation was evaluated by electrophoretic gel mobility shift
assay of whole-tissue homogenates. Results: Infusion of interleukin 1a
resulted in significant decreases in mean arterial pressure and systemic
vascular resistance, both of which were prevented by treatment with
dithiocarbamate. Pyrrolidine dithiocarbamate induced a significant
metabolic acidosis, whereas proline dithiocarbamate did not. Nuclear
factor k B–binding activity was increased within heart, lung, and liver
tissue 4 hours after interleukin 1a infusion. Treatment with dithiocar-
bamate resulted in decreased nuclear factor k B activation in lung and
liver tissue with respect to that in control animals. Conclusions: These
results demonstrate that nuclear factor k B is systemically activated dur-
ing whole-body inflammation and that inhibition of nuclear factor k B in
vivo attenuates interleukin 1a –induced hypotension. Nuclear factor k B
thus represents a potential therapeutic target in the treatment of hemo-
dynamic instability associated with the whole-body inflammatory
response. (J Thorac Cardiovasc Surg 1999;118:154-62)
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mortality.1-3 Systemic inflammatory response syn-
drome is thought to be initiated by contact activation of
complement and monocytes within the bypass circuit,
leading to the elaboration of various inflammatory
mediators including interleukin 1 a (IL-1 a ).4
Widespread circulation of IL-1a and other proximal
inflammatory cytokines results in the transformation of
vascular endothelium to an activation phenotype that
enhances vasomotor dysfunction, coagulation, and
leukocyte adhesion, further amplifying the hemody-
namic derangements associated with systemic inflam-
matory response syndrome.5
Quiescent monocytic and endothelial cells respond to
inflammatory stimuli and cell injury by activating sig-
nal transduction pathways that transmit signals through
the cytoplasm to the nucleus, resulting in the transcrip-
tion, translation, and expression of several genes
involved in systemic inflammatory states. Nuclear fac-
tor k B (NF-k B) is an inducible transcription factor that
binds with high affinity to specific sites in the promot-
er region of several inflammatory target genes to stim-
ulate gene expression in response to a diverse array of
inflammatory stimuli in vitro.6 The precise role of NF-
k B activation in vivo, however, has not been clearly
defined. In particular, it is unknown to what extent NF-
k B can be targeted transcriptionally to prevent dysreg-
ulation of systemic inflammation.
IL-1a induces significant hypotension when admin-
istered systemically to laboratory animals.7 IL-1a was
therefore administered to rabbits to create a simple
model of the hemodynamic insufficiency encountered
in systemic inflammatory states. We hypothesized that
IL-1a would systemically activate NF-k B in vivo and
that pharmacologic inhibition of this activation would
attenuate cardiovascular decompensation induced by
the inflammatory cytokine. To test these hypotheses
and assess any possible detrimental systemic effects of
NF-k B inhibition in vivo, the dithiocarbamate com-
pounds pyrrolidine dithiocarbamate (PDTC) and pro-
line dithiocarbamate (ProDTC) were used. Such com-
pounds have been shown in vitro to be specific potent
inhibitors of NF-k B.8
Methods
Reagents. PDTC was obtained from Sigma (St Louis, Mo).
ProDTC was provided by Norbert Frank, PhD (German
Cancer Research Center, Heidelberg, Germany). Human
recombinant IL-1a was a gift of Frank Chizzonite, PhD
(Hoffmann-LaRoche Inc, Nutley, NJ).
Rabbit model. New Zealand White rabbits weighing 3 to 4
kg were used in research protocols approved by the Animal
Care Committee of the University of Washington, Seattle. All
animals received humane care according to the “Guide for the
Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources and published by
the National Institutes of Health (NIH publication No. 86-23,
revised 1985). The rabbits were anesthetized with an initial
intramuscular injection of 35 mg/kg ketamine and 5 mg/kg
xylazine. They were intubated with an endotracheal tube
(inner diameter 3.0 mm) and maintained with inhaled 1%
halothane anesthesia in 100% oxygen with a tidal volume of
15 mL/kg for the duration of the study with a small-animal
ventilator. Minute ventilation was adjusted according to arte-
rial blood gas measurements to maintain arterial pH between
7.45 and 7.50 while keeping pCO2 between 25 and 35 mm Hg.
Body temperature was maintained at 36°C to 38°C with a
heating pad. In accordance with a standard cutdown tech-
nique, a 20-gauge flexible catheter was placed in the left
common carotid artery to continuously measure heart rate
and mean arterial pressure and to collect blood samples. A
double-lumen thermodilution probe and an injectate catheter
(model 94-011-3F; Baxter Healthcare Corporation Cardio-
Vascular Group, Irvine, Calif) were placed through the left
femoral artery and vein to measure core temperature and
cardiac output by thermodilution. A maintenance drip of
Ringer’s lactate solution (4-5 mL · kg–1 · h–1) was adminis-
tered and central venous pressure was measured with a 20-
gauge flexible catheter inserted into the right external jugular
vein. An additional 30 to 50 mL normal saline solution was
administered through the flushing of lines to maintain paten-
cy throughout the experiments. The cardiac output determi-
nations were performed in triplicate and the results were
averaged. SVR was calculated as follows:
SVR = (MAP – CVP) · 80/CO (dyn · s · cm–5).
where MAP was mean arterial pressure, CVP was central
venous pressure, and CO was cardiac output. After insertion
of the catheters, rabbits’ conditions were allowed to stabilize
for 30 to 60 minutes before baseline values were obtained.
Minute ventilation and tidal volume were not changed after
this baseline was established.
Study groups. Twenty-four rabbits were randomly
assigned to 4 groups (n = 6 per group; Table I) and monitored
for 240 minutes. Animals were intravenously treated with 1.0
mL phosphate-buffered saline solution (PBS) and PDTC or
ProDTC (15 mg/kg in 1 mL PBS) 60 minutes before intra-
venous infusion of IL-1a (5 m g/kg) or 1.0 mL saline solution
alone. Group 1 received PBS followed by saline solution.
Group 2 was given PBS before IL-1 a infusion. Group 3
received PDTC before the administration of IL-1a . Group 4
was treated with ProDTC before IL-1a infusion. Hemody-
namic parameters and arterial blood gas values were record-
Table I. Experimental groups and conditions
Experimental conditions
Group First treatment Second treatment
1 PBS Saline solution
2 PBS IL-1
3 PDTC IL-1
4 ProDTC IL-1
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ed at –60 minutes (baseline) and at 0, 30, 60, 120, 180, and
240 minutes after administration of saline solution or IL-1a .
Blood samples removed from the carotid catheter were
replaced with the same volume of saline solution. At the end
of 4 hours all animals were killed with 120 mg/kg intra-
venously administered concentrated pentobarbital. At that
time heart, lung, and liver tissues to be used for elec-
trophoretic mobility shift assay were snap-frozen in liquid
nitrogen and stored at –70°C.
Nuclear protein extractions. Aliquots of frozen tissue
were mixed with liquid nitrogen and ground to powder with
a motor and pestle. A 4-mL volume of solution A (0.6%
Nonidet P-40 [ICN Biomedical, Inc, Aurora, Ohio], 150
mmol/L sodium chloride, 10 mmol/L N-2-hydroxyethyl-
piperazine-N-2-ethanesulfonic acid, pH 7.9, 1 mmol/L ethyl-
enediaminetetraacetic acid, and 0.5 mmol/L phenylmethyl-
sulfonyl fluoride) were added to the mortar. The contents of
the mortar were placed in a Dounce tissue homogenizer
(Kontes Glass Company, Vineland, NJ), and the cells were
lysed with 5 strokes of the pestle. After transfer to a 15-mL
Fig 1. Hemodynamic parameters from rabbits in group 1 (PBS plus saline solution, open squares), group 2 (PBS
plus IL-1a , filled squares), group 3 (PDTC plus IL-1a , open circles), group 4 (ProDTC plus IL-1a , filled cir-
cles). Graphs depict absolute change from baseline value (–60 minutes) for mean arterial blood pressure (A) and
heart rate (B). Data are presented as mean for 6 rabbits in each group. Statistical significances of differences in
means (group effects) and time trends (time effects) were assessed for 4 groups as cross-sectional time series with
generalized estimating equations. P values from these analyses are represented in tables accompanying graphs.
A
B
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tube debris was pelleted by centrifugation at 2000 rpm for 30
seconds. The supernatant containing intact nuclei was trans-
ferred to 50-mL Corex tubes (Corning Incorporated Science
Products Division, Acton, Mass), incubated on ice for 5 min-
utes, and centrifuged for 10 minutes at 5000 rpm. Nuclear
pellets were then resuspended in 300 mL of solution B (25%
glycerol, 20 mmol/L N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid, pH 7.9, 420 mmol/L sodium chloride,
1.2 mmol/L magnesium chloride, 0.2 mmol/L EDTA, 0.5
mmol/L dithiothreitol, 0.5 mmol/L phenylmethylsulfonyl flu-
oride, 2 mmol/L benzamidine, 0.5 mg/mL pepstatin, 0.5
mg/mL leupeptin, and 0.5 mg/mL aprotinin) and incubated
on ice for 30 minutes. The mixture was then transferred to
microcentrifuge tubes and nuclei were pelleted by centrifuga-
tion at 14,000 rpm for 1 minute. Supernatants containing
nuclear proteins were saved, divided into aliquots, and stored
at –70°C. Protein quantitation was performed with the
Bradford assay.
Electrophoretic mobility shift assays. An oligonucleotide
containing the consensus sequence motif for NF-k B binding,
5´-a GTTGAGGGGACTTTCCCAGGC-3´ (Promega Corpor-
ation, Madison, Wis) was end-labeled with g -phosphorus
32–tagged adenosine triphosphate (Nycomed Amersham plc,
Little Chalfont, United Kingdom) by means of polynucleotide
kinase. Samples of nuclear protein extracts (20 m g) were incu-
bated for 20 minutes at 25°C with the phosphorus 32–end-
labeled, double-stranded oligonucleotide probe, underwent
electrophoresis in native 4% polyacrylamide gels, and were
autoradiographed. Cold competition was performed by adding
a 50-fold molar excess of specific unlabeled double-stranded
Fig 1. Cont’d. Graphs depict absolute change from baseline value (–60 minutes) for cardiac output (C) and SVR
(D). For complete legend, see Fig 1.
C
D
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probe to the reaction mixture for 20 minutes before the addi-
tion of the phosphorus 32–end-labeled oligonucleotide probe.
Statistical analysis. The hemodynamic and acid-base data
were analyzed as cross-sectional time series with generalized
estimating equations, a technique that is analogous to repeat-
ed-measures analysis of variance but has more flexibility,
allowing unequal spacing, unbalanced groups, and gaps.9 For
each of the 5 outcome parameters the absolute change from
baseline (–60 minutes) was modeled as the dependent vari-
able and the following elements were included as covariates:
the absolute baseline value of the outcome variable, log trans-
form of time, the group effect, and a set of group · time inter-
action terms to determine whether there was a statistically
significant difference among treatment groups with respect to
time trends in the outcome variable. The time trends for these
4 groups were compared overall and assessed for statistical
significance. The following 2 · 2 comparisons were made
among specific groups: group 1 versus group 2, group 2 ver-
sus group 3, group 2 versus group 4, and group 3 versus
group 4. Because our a priori hypotheses limited us to this
restricted set of 2 · 2 comparisons, multiple comparisons
adjustments were not made.
Results
Attenuation of interleukin 1a –induced hypoten-
sion in vivo by dithiocarbamates. The hemodynamic
effects of IL-1a administration and dithiocarbamate
advance treatment are demonstrated in Fig 1. Rabbits
in group 1 (saline solution control group) remained in
hemodynamically stable condition throughout the 5-
hour study period. Infusion of IL-1a (group 2) resulted
in a statistically significant reduction in mean arterial
pressure of approximately 10 mm Hg with respect to
the saline solution control group. Advance treatment
with ProDTC attenuated this cytokine-induced hypo-
tension (P = .08; Fig 1, A), whereas PDTC appeared to
have little effect on blood pressure. PDTC advance
treatment resulted in a significant increase in heart rate
and a reduction in cardiac output that was not seen with
ProDTC advance treatment (Fig 1, B and C).
IL-1a injection caused a significant reduction in
SVR with respect to that in the saline solution control
group (Fig 1, D). Dithiocarbamate advance treatment
repressed this IL-1 a –mediated reduction in SVR.
Advance treatment with PDTC appeared to have a
slightly greater and more prolonged effect in this
regard, but there was no statistically significant differ-
ence in SVR trends between the 2 dithiocarbamate-
treated groups.
Advance treatment with ProDTC appeared to inhibit
IL-1 a –mediated hypotension primarily through its
effects on SVR. Advance treatment with PDTC had
more complicated hemodynamic effects. The IL-
Fig 2. Acid-base status from rabbits in group 1 (PBS plus saline solution, open squares), group 2 (PBS plus IL-
1a , filled squares), group 3 (PDTC plus IL-1a , open circles), group 4 (ProDTC plus IL-1a , filled circles). Graph
depicts absolute change from baseline value (–60 minutes) for calculated base deficit. Data are presented as mean
for 6 rabbits in each group. Statistical significances of differences in means (group effects) and time trends (time
effects) were assessed for 4 groups as cross-sectional time series with generalized estimating equations. P values
from these analyses are represented in accompanying table.
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1a –mediated reduction in SVR was partially blunted
by PDTC advance treatment, but PDTC advance treat-
ment did not affect IL-1a –mediated hypotension, per-
haps because of the apparent cardiodepressive action
evidenced by its chronotropic and negative inotropic
effects.
Induction of metabolic acidosis by pyrrolidine
dithiocarbamate but not proline dithiocarbamate.
There were no significant differences in base deficit,
bicarbonate level, or arterial pH between the groups at
baseline before the administration of any treatment.
Infusion of IL-1a precipitated a metabolic acidosis
with a base deficit of approximately –10 mEq after 120
minutes (Fig 2). This change in the base deficit was sig-
nificantly greater than that seen in the saline solu-
tion–treated control animals. Rabbits that were treated
in advance with PDTC demonstrated a significant aug-
mentation of this IL-1a –associated base deficit (P =
.02), an effect that was not seen after advance treatment
with ProDTC.
Prevention of nuclear factor k B nuclear localiza-
tion in vivo by dithiocarbamates. To characterize the
ability of dithiocarbamates to inhibit intranuclear NF-
k B DNA–binding activity we used electrophoretic
mobility shift assay on nuclear proteins isolated from
tissue of rabbits in the IL-1a study groups. In rabbit
heart, lung, and liver, NF-k B DNA-binding activity
was markedly increased 240 minutes after IL-1a infu-
Fig 3. Autoradiographs from electrophoretic gel mobility shift assays of NF-k B activation in heart (A), lung (B),
and liver (C) tissue of rabbits after IL-1a administration with or without PDTC. Intravenous treatment with 15
mg/kg PDTC had little effect on IL-1a –induced NF-k B activation in rabbit heart tissue but resulted in inhibition
of IL-1a –induced NF-k B DNA-binding in rabbit lung and liver tissue 240 minutes after injection of 5 m g/kg IL-
1a . Lane 1, PBS plus saline solution; Lane 2, PBS plus IL-1a ; Lane 3, PDTC plus IL-1a ; Lane 4, cold compe-
tition, PBS plus IL-1a incubated with unlabeled probe. Position of inducible NF-k B–DNA complex is marked.
A B C
Fig 4. Autoradiographs from electrophoretic gel mobility shift assays of NF-k B activation in heart (A), lung (B),
and liver (C) tissue of rabbits after IL-1a administration with or without ProDTC. Intravenous treatment with 15
mg/kg ProDTC had little effect on IL-1a –induced NF-k B activation in rabbit heart tissue but resulted in inhibition
of IL-1a induced NF-k B DNA-binding in rabbit lung and liver tissue 240 minutes after the injection of 5 m g/kg
IL-1a . Lane 1, PBS plus saline solution; Lane 2, PBS plus IL-1a ; Lane 3, cold competition, PBS plus IL-1a incu-
bated with unlabeled probe; Lane 4, ProDTC plus IL-1a . Position of inducible NF-k B–DNA complex is marked.
A B C
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sion (Figs 3 and 4). In unstimulated heart and lung tis-
sue there was essentially no detectable NF-k B activa-
tion. NF-k B did appear to be constitutively expressed
in hepatic tissue. Advance treatment with PDTC or
ProDTC had little effect on NF-k B binding activity in
the heart (Figs 3, A, and 4, A). Advance treatment with
dithiocarbamate completely abolished the response to
IL-1a in the lung (Figs 3 B, and 4, B). Hepatic tissue
from rabbits treated with dithiocarbamate before IL-1a
injection showed a level of NF- k B binding that was
similar to constitutive levels and less than the NF-k B
activation observed in untreated rabbits that received
IL-1a (Figs 3 C, and 4, C). Addition of 50-fold molar
excess unlabeled, consensus sequence NF-k B oligonu-
cleotide (cold competition) to the nuclear protein sam-
ples successfully competed for NF-k B binding, elimi-
nating the distinct band and indicating the specificity of
the NF-k B DNA–binding complex.
Discussion
The principal goals of therapy in the treatment of
cytokine-induced shock should be prevention of host
cell activation, inhibition of secondary mediators of
cellular injury, and limitation of end-organ damage.l0
Current therapeutic interventions for systemic inflam-
matory response syndrome have failed to clearly
demonstrate a clinical benefit, perhaps because they
focus on inhibition of single distal components of the
overall inflammatory response. Inflammation, howev-
er, is initiated and amplified by many redundant and
overlapping molecular pathways. We therefore focused
on the common control points shared by these mecha-
nisms as targets for novel therapies to treat systemic
inflammatory response syndrome. Transcriptional reg-
ulation of a set of inflammatory genes activated by
cytokines may be a focal point in this process.
The role of NF-k B in the transcriptional activation of
key inflammatory genes has been extensively studied
in primary and transformed cell lines in vitro. We have
shown for the first time that NF-k B is activated in vivo
in multiple organs in response to IL-1a administration.
In this animal model of systemic inflammation we
demonstrated the ability of PDTC to inhibit the activa-
tion of this transcription factor within lung and liver tis-
sue. Further, this study demonstrated the ability of the
less toxic dithiocarbamate ProDTC to inhibit in vivo
NF-k B activity. The ability of ProDTC to inhibit NF-
k B has never before been examined.
ProDTC was able to attenuate IL-1a –induced hypo-
tension primarily by inhibiting the IL-1a –mediated
decrease in SVR. PDTC was less effective at modulat-
ing these cytokine-induced hemodynamic changes. The
observed attenuation of cytokine-induced hemodynam-
ic decompensation was associated with a decreased
nuclear appearance of NF-k B complexes in rabbit tis-
sue. Dithiocarbamates block NF-k B and prevent the
expression of vascular cell adhesion molecule 1 and
intracellular cell adhesion molecule 1 in human
endothelial and fibroblast cells in vitro.11-13 Expression
of chemotactic cytokines is also prevented by dithio-
carbamate treatment.14 Disruption of NF-k B nuclear
binding activity in vivo may have interrupted leukocyte
trafficking and reduced organ inflammation, subse-
quently preventing leukocyte-mediated damage to the
microvasculature. The hemodynamic stability observed
in ProDTC-treated animals may have resulted from
reduced intravascular fluid extravasation and improved
hemodynamics related to reduced neutrophil accumu-
lation within the tissue microvasculature, presumably
resulting in decreased loss of endothelial barrier func-
tion. Alternatively, dithiocarbamate treatment may
have reduced production of nitric oxide by inducible
nitric oxide synthase in response to IL-1a . Multiple
NF-k B binding sites exist within the promoter region
of the inducible nitric oxide synthase gene, and dithio-
carbamates prevent induction of inducible nitric oxide
synthase in cultured macrophages.15
One unexpected finding in this study was that
although PDTC is effective at blocking NF-k B in vitro,
it induces a toxic metabolic acidosis in vivo. In con-
trast, no acidosis was noted with ProDTC treatment
alone. Animals treated with saline solution or ProDTC
did not show a significant acidosis until after they
received IL-1a , suggesting that the cytokine was pri-
marily responsible for the moderate acidosis observed.
These changes cannot be attributed to differences in
ventilation because the ventilatory settings were not
altered after similar and stable baseline blood gas mea-
surements had been attained in each group. ProDTC is
known to behave similarly to other dithiocarbamates,
with much less toxicity and greater stability in vivo,
increasing the availability of the parent compound.16
As a consequence compounds such as ProDTC might
exhibit superior activity against NF-k B activation in
vivo with fewer toxic side effects.
We have shown for the first time that NF-k B activation
is associated with severe IL-1a –induced hypotension.
PDTC was previously shown to be a potent inhibitor of
NF-k B in vitro. We have now shown that ProDTC can
also act as a powerful inhibitor of NF-k B, and it appears
to be both more active and less toxic in vivo than PDTC.
This study indicates that dithiocarbamates can be used as
pharmacologic inhibitors of NF-k B to study the contri-
butions of this transcription factor to systemic inflam-
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mation and other disease states, including neointimal
formation, arteriosclerosis, transplant rejection, and
ischemia-reperfusion injury. The inhibition of transcrip-
tion factor activity represents an important approach to
understanding the pathogenesis of dysregulation of
inflammatory disease processes in vivo.
We thank Robert Thomas, Christine Rothnie, Wang Yun,
MD, and Ellen Collins for their assistance in the laboratory.
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Discussion
Dr Donald Glower (Durham, NC). The study has several
new aspects that I think are intriguing and of potential future
importance. First, you have clearly demonstrated a new class
of anti-inflammatory agents, the NF-k B transcriptional factor
inhibitors, and have shown for the first time that 2 of those
agents do inhibit inflammatory response in multiple organs in
vivo. Second, this is the second study that has shown that
inhibition of the NF-k B transcriptional factor itself decreases
systemic inflammatory response. Finally, in looking at 2 of
these new agents you showed that one of them, ProDTC,
appears to have fewer side effects and is potentially more
interesting clinically.
These studies thus have broad significance not only in the
field of basic immunology but in the field of clinical thoracic
surgery, in which surgeons encounter many of the unfavor-
able side effects of the systemic inflammatory response to
cardiopulmonary bypass. I think that this new class of agents,
the NF-k B inhibitors, has promise in attenuating the effects
of cardiopulmonary bypass.
I have 2 main questions for you along these lines. First, you
looked at a simple model of systemic inflammatory response
in the rabbit. Do you have any experience regarding these
agents in blocking the inflammatory response to cardiopul-
monary bypass? Second, do you foresee any potential diffi-
culties in applying this class of agents to cardiopulmonary
bypass?
Mr Kovacich. Thank you for the questions. First of all, this
was indeed a relatively simple model of systemic inflamma-
tion. Our main goals with this study were (1) to see whether
NF-k B was actually activated in multiple organ systems to
respond to inflammatory stimuli and (2) to determine
whether we could inhibit this response pharmacologically.
We do not at this time have any experience in using these
agents in a specific model of cardiopulmonary bypass. We do
have some preliminary data from small-animal models of
both global and regional myocardial ischemia-reperfusion in
which we have been able to show that NF-k B is activated. On
the basis of our initial results with these myocardial
ischemia-reperfusion models, it appears that these dithiocar-
bamate compounds are able to inhibit NF-k B activation stim-
ulated by ischemia-reperfusion, and this inhibition is corre-
lated with a reduction in tissue injury related to myocardial
ischemia-reperfusion. We do have plans underway to perform
some large-animal porcine studies. We plan to test the ability
of these agents to ameliorate the systemic inflammatory
changes seen in a pig model of cardiopulmonary bypass.
Specifically, we will examine the effects of these drugs on
several end points of inflammation, including tissue edema
and neutrophil accumulation in multiple organs, histologic
162 Kovacich et al The Journal of Thoracic and
Cardiovascular Surgery
July 1999
inflammatory changes, organ function, and hemodynamic
parameters.
Dr Glower. This is a relatively new class of drug. Given
what we do know about the inflammatory response to car-
diopulmonary bypass, do you hypothesize that NF-k B is a
fairly central part of that response? Do you hope that a single
agent such as an NF-k B blocker might be all that you would
need to dramatically reduce the inflammatory response to
cardiopulmonary bypass, or are there other aspects of the
inflammatory response that are not known to be inhibited by
NF-k B blockers and might need additional agents? For exam-
ple, if we used one of these agents, would we need to use
steroids in addition to block the inflammatory response?
Mr Kovacich. One of the reasons that we targeted NF-k B
is that extensive in vitro data suggest that it is involved in the
transcriptional regulation of a wide variety of known inflam-
matory mediators. As you know, one of the problems with the
inflammatory response is that it is highly redundant and thus
extremely difficult to block effectively at specific points. In
our view, by targeting a common control point in the tran-
scriptional regulation of these inflammatory genes we might
more effectively attenuate dysregulation of inflammatory
responses. NF-k B activation appears to be an example of
such a convergence point in the inflammatory cascade.
Because NF-k B does appear to be required for so many dif-
ferent genes, it is our hope that targeting this specific mecha-
nism will allow us to attenuate the inflammatory response
overall with only a single agent.
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